Alessandro Corso

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal et al. · New England Journal of Medicine · 2007 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +14

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge et al. · New England Journal of Medicine · 2012 · 739 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini et al. · The Lancet Haematology · 2020 · 554 citations · Full text

Medicine, Hematology, Oncology +16

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

Marzia Varettoni, Alessandro Corso, Gian-Matteo Pica et al. · Annals of Oncology · 2009 · 486 citations

Medicine, Hematology, Internal Medicine +14

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11